Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
IRVINE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 22, 2024 Category: Pharmaceuticals Source Type: clinical trials
Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure
Conditions: Lyme Disease; Post-Treatment Lyme Disease; Chronic Lyme Disease; Tick-Borne Infections; Pregnancy Complications; Child Development Intervention: Other: Neurodevelopmental assessments and follow-up Sponsors: Children's National Research Institute; Clinical Trials Network for Lyme and Other Tick-Borne Diseases; Steven & Alexandra Cohen Foundation Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
Condition: Lyme Disease Interventions: Biological: mRNA-1975; Biological: mRNA-1982; Biological: Placebo Sponsor: ModernaTX, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials